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Previous studies have established that pro-oxidative stressors suppress host immunity due to their 
ability to generate oxidized glycerophosphocholine (Ox-GPC) lipids with Platelet-activating 
Factor-receptor (PAF-R) agonist activity.  Because many chemotherapeutic agents also induce 
reactive oxygen species, the present studies were designed to define if chemotherapeutic agents 
could thwart host anti-tumor immunity against melanoma via PAF-R activation. We demonstrate 
that treatment of melanoma cell lines in vitro and tumors in vivo with chemotherapeutic agents 
generates PAF-R-agonists in a process blocked by antioxidants, indicating the involvement of 
non-enzymatic PAF-R-agonists in this event. In a model system consisting of implantation of 
two tumors, we show that intratumoral chemotherapy with melphalan or etoposide of one tumor 
significantly augments the growth of the other (untreated) tumor in wild-type but not PAF-R-
deficient hosts. Chemotherapeutic agents-mediated PAF-R-dependent increased tumor growth is 
blocked by systemic administration of antioxidants and cyclooxygenase-2 inhibitors. In addition, 
depleting antibodies against regulatory T cells (Tregs) significantly attenuated chemotherapy-
mediated growth of untreated tumors, suggesting the role of Tregs in this process. Moreover, 
using FoxP3EGFP transgenic mice, we show that COX-2 inhibitor blocked intratumoral Tregs, 
indicating that Tregs are downstream to COX-2. Furthermore, PAF-R agonists were identified in 
perfusates of patients undergoing isolated limb chemoperfusion for melanoma with melphalan 
chemotherapy.  Finally, various novel Ox-GPCs are identified after chemotherapy by mass 
spectrometry. These findings provide evidence for a novel and previously unappreciated pathway 
by which Ox-GPC PAF-R agonists produced as a by-product of chemotherapy modulate tumor 
growth via the inhibition of anti-tumor immunity.  These studies might explain some instances of 
chemotherapy treatment failure and offer insights into potential therapeutic strategies that could 
enhance the overall anti-tumor effectiveness of chemotherapy.  
 
 
